Global Impact of the COVID-19 Pandemic on Cerebral Venous Thrombosis and Mortality

Authors	NGUYEN Thanh N QURESHI Muhammad M KLEIN Piers YAMAGAMI Hiroshi ABDALKADER Mohamad MIKULÍK Robert SATHYA Anvitha MANSOUR Ossama Yassin CZLONKOWSKA Anna LO Hannah FIELD Thalia S CHARIDIMOU Andreas BANERJEE Soma YAGHI Shadi SIEGLER James E ŠEDOVÁ Petra KWAN Joseph AGUIAR de Sousa Diana DEMEESTERE Jelle INOA Violiza OMRAN Setareh Salehi ZHANG Liqun MICHEL Patrik STRAMBO Davide MARTO Joao Pedro NOGUEIRA Raul G
Year of publication	2022
Type	Article in Periodical
Magazine / Source	JOURNAL OF STROKE
MU Faculty or unit	Faculty of Medicine
Citation
Web	STROKE
Doi	http://dx.doi.org/10.5853/jos.2022.00752
Keywords	COVID-19; Cerebral venous thrombosis; Vaccine-induced immune thrombotic thrombocytopenia; Mortality; SARS-CoV-2; Stroke
Description	Since the first case in December 2019, coronavirus disease 2019 (COVID-19) has been responsible for more than 340 million infections and over 5.5 million deaths.1 Though most of the morbidity and mortality associated with COVID-19 is related to pulmonary complications, the disease has had wide-ranging systemic effects, including a range of neurological manifestations2,3 and disruption of coagulation homeostasis.4-7 This disruption in normal coagulation may trigger abnormal clotting events such as venous thromboembolism and stroke.8-10 Cerebral venous thrombosis (CVT) is a rare cause of stroke caused by the formation of clots in the brain’s venous system. The incidence of CVT has been reported to increase over the last decade, either from changing risk factors or improved detection.11-13 Compared to other forms of stroke, the incidence of CVT is more common in younger patients and women. CVT generally has a favorable prognosis with a good 90-day neurological outcome seen in greater than 80% of patients.